Aarti Pharmalabs Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹610 Cr +45.9% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
AP

Aarti Pharmalabs Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Aarti Pharmalabs Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹418Cr
−8.7% YoY
+8.3% QoQ
Net profit
₹28Cr
−49.1% YoY
−44% QoQ
Margin
18%
−2 pp YoY
−6 pp QoQ
Price₹817
Market cap₹6.2K Cr
P/E35.0

The short version

CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth. FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4).

From Aarti Pharmalabs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth.
  • New molecules moving from development to commercial phase will drive sales, with larger growth anticipated in FY '27 and beyond.
  • API business to normalize and ramp up in H2 FY '26 after inventory corrections and product mix optimization, including oncology and steroid APIs, with major launches in FY '27 and FY '28.
  • Atali plant will become fully operational in 2-3 quarters, boosting Intermediate and CDMO business revenue from FY '27 onward.
  • Xanthine capacity expansion to 9,000 tons/year by end of FY '26, with gradual ramp-up over 2-3 years expected to capture ~25% market share.

2 more points from Aarti Pharmalabs Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Aarti Pharmalabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue.
  • Xanthine expansion: Capacity increased from 5,000 to 9,000 metric tons (annual installed capacity) by end of FY '26; expansion is brownfield with phased operationalization.
  • Facility upgrades: Focus on debottlenecking and standardizing production, including at Ganesh Polychem to improve cost efficiency and profitability.
  • Site shifting plan: Future plan to shift Dombivli site within the year as part of strategic operational improvements.

2 more points from Aarti Pharmalabs Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Aarti Pharmalabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The CDMO-CMO segment currently has 59 active projects, with 39 in the commercial stage and 20 under various stages of development at the customer's end.
  • The company is working with 21 customers in this segment and is on track to achieve and exceed the earlier estimated sales target of 30% to 40% Y-o-Y growth.
  • Management is actively participating in several RFPs (Requests for Proposals) to increase the CDMO project funnel, including expanding geographical presence in Europe and North America to boost business development.

2 more points from Aarti Pharmalabs Ltd's call on order book

Create a free account to keep reading this call

Aarti Pharmalabs Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Aarti Pharmalabs Ltd Q2 FY26 results — key figures

Aarti Pharmalabs Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue418458-8.7%386+8.3%
Operating profit (EBITDA)7494-21.3%93-20.4%
Operating margin18%20%-2 pp24%-6 pp
Profit before tax3972-45.8%65-40%
Net profit (PAT)2855-49.1%50-44%
EPS (₹)3.086.03-48.9%5.46-43.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹610 Cr, net profit ₹71 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Aarti Pharmalabs Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Aarti Pharmalabs Ltd Q2 FY26 results?

CDMO business is expected to exceed earlier 30%-40% growth guidance in FY '26, with substantial sales in H2 and next year contributing to overall revenue growth. FY '26 EBITDA growth guidance revised to 8%-12% year-on-year, despite challenges (Page 4).

What is Aarti Pharmalabs Ltd share price analysis?

Aarti Pharmalabs Ltd currently shows a neutral. The stock trades at a P/E of 35.0 with a market cap of ₹6,193 Cr. Investors should review the full earnings analysis for detailed insights.

Is Aarti Pharmalabs Ltd planning capital expenditure?

Atali plant: INR 450 crore CAPEX, inaugurated in September 2025, started operations with trial batches; expected to be fully operational in 2-3 quarters (by FY '27) to contribute meaningfully to revenue.

Keep Aarti Pharmalabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.